Updates on Rozanolixizumab and Zilucoplan To Treat Myasthenia Gravis

Current Myasthenia Gravis Treatment Options are LimitedПодробнее

UCB Announces Positive Phase 3 Results for Zilucoplan in Generalized Myasthenia GravisПодробнее

Mechanism of Action of Rozanolixizumab to Treat Myasthenia GravisПодробнее

Employee's Frustration Led to Drug Development for Myasthenia GravisПодробнее

Zilucoplan Explained: How This New Drug Works for Myasthenia Gravis │ PharmacologyПодробнее

Advancing myasthenia gravis treatment: RAISE trial of zilucoplanПодробнее

Research Webinar: Update on RozanolixizumabПодробнее

UCB Announces Phase 3 Results for Zilucoplan and Rozanolixizumab in Generalized Myasthenia Gravis (gПодробнее

Efficacy and Safety of Rozanolixizumab to Treat Myasthenia GravisПодробнее

Research Webinar Series: New Treatment for Generalized Myasthenia GravisПодробнее

PT IV | How Do You Treat MG? | Myasthenia Gravis Awareness Month series with Amit Sachdev, MD, MSПодробнее

Overview of Myasthenia GravisПодробнее

cosMOG: anti-FcRn agent rozanolixizumab for relapse prevention in MOGADПодробнее

Two Different Approaches in the Treatment of gMG.Подробнее

Clinical Trials Update: Ra Pharma, Momenta & argenxПодробнее

Patient Experience in Clinical Trials for Myasthenia GravisПодробнее

Updates on Treatment for MGПодробнее

FDA Approves Zilucoplan for Generalized Myasthenia Gravis in AChR Antibody-Positive AdultsПодробнее

Research Updates in Myasthenia GravisПодробнее